The Centre has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines, a move expected to reduce the prices of some cancer drugs by up to 70% and save patients an estimated ₹2,500 crore annually. The decision, announced on October 8, 2026, aims to make cancer treatment more affordable by limiting mark-ups across the medicine supply chain.
What Is the Centre’s New Cancer Drug Pricing Policy?
The Indian government has announced a new measure to control the cost of cancer medicines by restricting trade margins on non-scheduled anti-cancer drugs to 30% of their maximum retail price (MRP). The policy extends price protection to medicines that do not fall under the existing scheduled drug price-control framework.
Cancer treatment can involve repeated chemotherapy sessions, targeted therapies, immunotherapy and other specialised medicines. For families managing treatment over several months, the cost of medicines can become a substantial financial burden, particularly when patients require expensive branded or imported drugs.
Under the new measure, the government intends to limit the mark-ups added as medicines move through the supply chain before reaching patients. The Department of Pharmaceuticals has said the decision could reduce medicine prices by up to 70% and generate annual savings of approximately ₹2,500 crore.
However, these figures are government estimates, not guaranteed savings for every patient. The actual reduction will depend on the medicine concerned, its existing price structure and the final implementation of the policy.
Scheduled and Non-Scheduled Cancer Drugs: What Is the Difference?
India already regulates the prices of several essential medicines under the Drugs (Prices Control) Order, 2013. The National Pharmaceutical Pricing Authority (NPPA), which operates under the Department of Pharmaceuticals, fixes ceiling prices for scheduled formulations and retail prices for certain new drugs under the applicable rules.
Scheduled medicines are subject to government-fixed price limits. Manufacturers must sell these medicines within the applicable ceiling prices, subject to permitted taxes and other provisions.
Non-scheduled medicines operate under a different framework. Their prices are not subject to the same scheduled-drug ceiling-price mechanism, although they remain subject to applicable regulations. Before the latest announcement, manufacturers of non-scheduled formulations were generally restricted from increasing their MRP by more than 10% over the preceding 12 month
The newly announced trade-margin measure adds another layer of regulation specifically targeting non-scheduled anti-cancer medicines. It seeks to address the difference between the cost at which medicines enter the supply chain and the price ultimately paid by patients.
This distinction matters because a medicine not covered by the existing scheduled price list could still be expensive even when other cancer drugs are already subject to government price controls.
How the 30% Trade Margin Cap Could Reduce Cancer Drug Prices
Trade margins represent the difference between the price at which a product is bought and the price at which it is sold through the distribution chain, subject to the applicable pricing structure. In pharmaceuticals, manufacturers, distributors, stockists and retailers may all play a role in getting medicines to patients.
When the mark-ups accumulated along this chain are high, the final retail price can become substantially greater than the initial supply price. This is particularly concerning for expensive cancer medicines, where even a modest percentage increase can translate into thousands of rupees.
The government’s new measure aims to restrict these margins and bring down the maximum retail prices of covered medicines. The potential impact is significant for patients who need repeated doses or long-term treatment
Consider a hypothetical example of a cancer medicine with a current MRP of ₹10,000. If the price of that medicine falls by 20% following implementation, the patient would pay ₹8,000, saving ₹2,000 per purchase. If the patient requires several purchases, the savings could accumulate over the course of treatment.
This example illustrates how a price reduction can affect household spending. It does not represent an actual price notification or a confirmed reduction for any specific drug.
The government’s estimate that prices could fall by up to 70% should also be understood carefully. It does not mean every cancer medicine will become 70% cheaper. The reduction will vary according to the existing trade margins, the medicine’s current pricing and the applicable implementation rules.
Which Cancer Medicines Will Come Under the New Rules?
The policy targets non-scheduled anti-cancer drugs. Government information indicates that the measure is intended to extend price protection to medicines outside the scheduled list, including products across different market segments.
Reporting on the announcement has indicated that the coverage is expected to include branded and generic medicines, as well as domestic and imported products. The exact medicines covered will depend on the final list and applicable government notifications.
An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines covered by the measure, according to the government’s announcement. Patients should therefore avoid assuming that every medicine prescribed for cancer will automatically receive the same price reduction.
The distinction is important for patients receiving targeted therapies or other specialised treatments. Two medicines used for the same cancer may have different prices and regulatory treatment, depending on their formulation and classification.
Patients should check the exact name, strength and formulation of their prescribed medicine before comparing prices. They should also ask their hospital pharmacy or treating oncologist whether the medicine falls under the new policy once the relevant list and implementation details are officially available.
What the Policy Means for Patients in Tier-2 and Tier-3 Cities
For families in cities such as Nagpur, Nashik, Indore, Bhopal, Kanpur and other smaller urban centres, medicine affordability is closely linked to access to treatment.
Patients may need to travel to larger cities for specialised cancer care, adding transport, accommodation, diagnostic tests and lost wages to their medical expenses. The cost of medicines is only one part of the overall financial burden, but it can be a major recurring expense.
A reduction in the price of a covered cancer medicine could help families manage treatment budgets more effectively. It may also reduce the pressure on relatives who contribute to medical bills or borrow money to fund ongoing care.
The benefits, however, will depend on whether the patient’s prescribed medicine is included and whether the revised price is reflected in actual sales. A trade-margin cap does not directly reduce every component of cancer care, including hospital charges, surgery, radiation therapy, diagnostic services and medicines outside the policy’s scope.
Patients should continue to follow their doctors’ prescriptions and should not delay treatment while waiting for prices to change. Hospitals, pharmacies and healthcare providers will also have a role in communicating updated prices once the relevant notifications take effect.
Implementation and Monitoring: What Happens Next?
The announcement is an important policy development, but the practical impact will depend on implementation. The government has stated that an expert committee under the DGHS will finalise the list of medicines covered by the new measure. The relevant notifications and implementation details will determine how the cap applies to individual products.
The NPPA plays a central role in India’s drug-price regulation. Its responsibilities include fixing prices for scheduled formulations, setting prices for certain new drugs and taking action under the applicable rules when necessary. Its existing framework will be relevant to monitoring the broader drug-pricing system, although the precise enforcement arrangements for this new measure will depend on the government’s final directions.
For patients, the most useful indicator will be the actual price displayed and charged for a covered medicine. A policy announcement alone does not establish that every pharmacy has already reduced its prices.
Patients and caregivers should retain bills, check the MRP printed on medicine packaging and seek clarification if the price charged does not match the applicable notified price. They should also ask their hospital pharmacy about any revised prices for medicines included in the final list.
Why Cancer Drug Affordability Remains a Major Healthcare Issue
Cancer treatment can place a prolonged financial burden on Indian households. Depending on the diagnosis, treatment may require surgery, chemotherapy, radiation, targeted medicines, immunotherapy and follow-up care. Some patients need multiple therapies over an extended period.
India has already taken steps to regulate essential cancer medicines. In March 2026, the government reported that ceiling prices for 131 scheduled anti-cancer formulations were effective, with estimated annual savings of around ₹294 crore resulting from price reductions under the existing framework
The latest decision seeks to extend protection further by addressing trade margins on non-scheduled cancer medicines. Its significance lies in targeting a part of the pricing structure that can contribute to the final amount paid by patients.
Ultimately, the policy’s success will be judged by its implementation, compliance across the supply chain and the actual savings achieved by patients. Lower medicine prices could offer meaningful relief, but affordability will also depend on access to hospitals, insurance coverage, timely diagnosis and the availability of prescribed treatments.
Key Takeaways
- The Centre announced a 30% cap on trade margins for non-scheduled anti-cancer medicines on October 8, 2026.
- The government estimates that the measure could reduce prices by up to 70% and save patients approximately ₹2,500 crore annually.
- An expert committee under the DGHS will finalise the list of medicines covered by the policy.
- Actual savings will vary by medicine, and patients should verify notified prices rather than assume every cancer drug will become cheaper by the same amount.
Frequently Asked Questions
1. What is the new cancer drug price cap in India?
The Centre has announced a 30% cap on trade margins for non-scheduled anti-cancer medicines. The measure aims to limit mark-ups in the medicine supply chain and reduce the prices paid by patients.
2. Will cancer medicines become 70% cheaper?
Not necessarily. The government estimates that prices could fall by up to 70%, but the actual reduction will depend on the medicine’s existing price structure and the applicable rules.
3. Does the policy cover all cancer medicines?
The measure targets non-scheduled anti-cancer medicines. The exact coverage will depend on the final list issued under the policy. Scheduled medicines already operate under the applicable government price-control framework.
4. How can patients check whether their medicine is covered?
Patients should check the final government notification, confirm the exact medicine and formulation with their hospital pharmacy, and compare the applicable notified price with the price charged.
